IDEAYA ($IDYA): What Does the Darovasertib Registrational Path Rest On?

01 What IDEAYA is building

IDEAYA Biosciences is a South San Francisco precision-oncology company founded and led by Yujiro S. Hata. Its scientific identity is broader than the phrase “synthetic lethality,” although that concept remains central. The company tries to identify genetic or molecular dependencies that make a tumor unusually vulnerable to a targeted intervention, select patients with biomarkers and then combine assets when a second mechanism may deepen or prolong response.

The portfolio now sits in four practical clusters:

• PKC inhibition in uveal melanoma: darovasertib, the lead value driver, used with crizotinib in metastatic disease and as a monotherapy or combination in primary-disease settings.
• ADC plus DNA-damage response: IDE849, a DLL3-targeted TOP1-payload ADC; IDE034, a B7H3/PTK7 bispecific TOP1 ADC; and IDE161, a PARG inhibitor intended to enhance TOP1 lesion accumulation and potentially deepen ADC responses.
• The MTAP pathway: IDE397, a MAT2A inhibitor, and IDE892, an MTA-cooperative PRMT5 inhibitor that entered Part 2 monotherapy expansion on July 27, with a wholly owned combination strategy, a Roche-supplied pan-RAS combination and a future CDKN2A-deficiency program.
• Epigenetic dependency: IDE574, an oral dual KAT6/7 inhibitor in Phase 1.

The business model mixes wholly owned development, regional licensing and clinical supply collaborations. IDEAYA owns U.S. darovasertib rights. Servier owns ex-U.S. development and commercial rights and is responsible for regulatory and commercial activity outside the United States. IDEAYA received a $210 million upfront payment and can receive development, regulatory and commercial milestones plus mid-teens to low-twenties royalties on ex-U.S. net sales, according to the Q1 2026 filing. For IDE849, Jiangsu Hengrui retains Greater China while IDEAYA controls rights outside Greater China and owes milestones and royalties. Roche and AstraZeneca are supplying combination agents in defined clinical collaborations, but those arrangements are not broad asset-level validation or a purchase commitment.

Why the architecture matters

A deep pipeline is only valuable if the company can fund it, prioritize it and kill weak programs. IDEAYA has shown both expansion and pruning. It deprioritized the IDE397/Trodelvy combination, and after GSK terminated its collaboration the company said it planned to discontinue IDE275, a WRN inhibitor, and IDE705, a Pol Theta inhibitor, while evaluating strategic options. That is painful because it removes previously advertised options, but it is also evidence that management is willing to stop spending when ownership, fit or probability of success changes.

What Would Falsify This Reading

In Merlintrader’s view, IDEAYA is a company that has one asset close to a filing and enough cash to find out whether the rest of the pipeline is worth anything, which is a rare combination. Each of the following would contradict that reading directly, and each is checkable against a primary document.

• The darovasertib filing does not complete, or is not accepted. The nearest item is the registrational path for darovasertib in uveal melanoma. A rolling submission that stalls, or an application refused filing, removes the only part of the story that is close to a decision.
• Overall survival follow-up does not hold. The registrational case rests on data that continue to mature. A survival curve that converges as follow-up lengthens would change what the application is asking the agency to approve, and it would do so before any regulatory date.
• The spending curve outruns the balance sheet. Research and development was $108.7 million in the second quarter of 2026 against $74.2 million a year earlier, and operating activities used $163.4 million in the half against $122.8 million. Against about $1.24 billion of cash and marketable securities that gives a historical cash cushion, whose adequacy changes with the spending plan: the twelve-month statement in the filing is a statement about the current plan, not about an expanded one.
• The collaboration revenue does not recur. Collaboration revenue was $8.9 million in the quarter, versus zero in the comparable prior-year quarter. If it is a one-off recognition rather than the start of a partnered stream, reliance on existing liquidity and future financing would increase.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

02 Darovasertib: the asset that changed the story

Darovasertib is an oral inhibitor of protein kinase C, or PKC. Uveal melanoma is molecularly distinct from cutaneous melanoma. Activating changes in GNAQ or GNA11 are common drivers, and PKC sits downstream in the signaling pathway. The therapeutic thesis is that suppressing PKC attacks a central oncogenic dependency. Crizotinib inhibits c-MET, a pathway implicated in resistance and adaptive signaling, so the combination is designed to produce a more complete and durable block than darovasertib alone.

IDEAYA originally licensed the molecule, then known as LXS196, from Novartis in 2018. That origin matters because darovasertib is not an internally discovered molecule, and milestone and royalty obligations exist. It does not invalidate the economics, but investors should treat gross product revenue and net economic value as different concepts.

OptimUM-02 design

OptimUM-02 is a randomized Phase 2/3 registrational study in first-line HLA-A*02:01-negative metastatic uveal melanoma. The combination of darovasertib and crizotinib was compared with investigator’s choice of treatment. This population is central because Kimmtrak, the first systemic therapy approved specifically for metastatic uveal melanoma, is limited to HLA-A*02:01-positive patients. The HLA-negative group therefore represents a clearly identifiable area of unmet need.

The Phase 2 component used progression-free survival as the key endpoint intended to support a potential accelerated-approval strategy. Overall survival is the primary endpoint of the Phase 3 portion and is intended to support potential full approval when sufficiently mature. This dual framework is why PFS and OS need to be assessed separately. The trial can deliver a compelling PFS result while OS remains unresolved.

The most common grade 3/4 treatment-related events in the combination arm included diarrhea at 10.0%, syncope at 7.1% and hypotension at 3.8%. Median relative dose intensity was 91.0% for darovasertib and 77.1% for crizotinib. Discontinuations due to treatment-related adverse events were 2.5% for darovasertib and 10.0% for crizotinib, compared with 19.0% for investigator’s choice.

The FDA path: what RTOR means and what it does not

The FDA agreed to review the darovasertib application under the Oncology Center of Excellence’s Real-Time Oncology Review program. IDEAYA completed its first pre-submission in May and targets completion of the NDA in the second half of 2026. RTOR allows portions of a complete application to be reviewed before formal completion. It can improve review efficiency and communication. It does not lower the legal standard for approval, promise accelerated approval, guarantee acceptance of the filing or establish a decision date.

The company has described PFS as supporting a potential U.S. accelerated approval and future OS data as supporting potential full approval in the United States and globally. The exact regulatory outcome may depend on data maturity, confirmatory obligations, manufacturing, safety, inspection readiness, statistical details and the FDA’s judgment regarding benefit-risk in the target population. “RTOR accepted” does not mean “approval is certain.”

Why OS still matters even if accelerated approval is granted

Overall survival matters for at least four reasons. First, it may be required to convert an accelerated approval into traditional approval. Second, physicians and guidelines may view the regimen differently if PFS improves without a persuasive OS direction. Third, insurers and health-technology assessment bodies outside the United States may demand survival and quality-of-life context. Fourth, the stock’s multiple depends on whether darovasertib is perceived as a durable standard rather than a temporary bridge.

OS in metastatic uveal melanoma can be difficult to interpret because subsequent therapies, liver-directed procedures and patient heterogeneity can dilute or confound separation. That challenge cuts both ways: maturity can take time, but uncertainty should not be ignored simply because PFS was strong.

03 Darovasertib beyond HLA-negative metastatic disease

The first filing population may be only the beginning. The long-term franchise thesis rests on three expansion vectors: HLA-positive metastatic disease, neoadjuvant treatment before local therapy and adjuvant treatment to prevent relapse.

OptimUM-01: HLA-A*02:01-positive metastatic uveal melanoma

IDEAYA completed enrollment of roughly 100 HLA-positive patients in a single-arm Phase 2 cohort of darovasertib plus crizotinib. ESMO 2026 will feature results from more than 85 efficacy-evaluable patients. This is commercially meaningful because HLA-positive patients already have an approved systemic option, Kimmtrak, and therefore the evidence bar is different. A single-arm response signal can support medical interest or future regulatory discussions, but it cannot directly demonstrate superiority to Kimmtrak.

The strategic opportunity is not necessarily a winner-take-all replacement. Darovasertib could be considered for patients unable to receive or continue weekly intravenous therapy, for sequencing after another agent, or for a subgroup where efficacy and tolerability appear attractive. Those are hypotheses, not shown clinical positions. The ESMO dataset should be judged on response depth, PFS, OS, duration, prior therapy, liver-disease burden and safety — not ORR alone.

OptimUM-09 and OptimUM-10: neoadjuvant primary uveal melanoma

Neoadjuvant darovasertib aims to shrink a primary ocular tumor before definitive local therapy. The clinical ambition is unusually tangible: if a tumor shrinks enough, a patient recommended for enucleation might preserve the eye, or a patient receiving plaque brachytherapy might receive a smaller radiation field and retain more function. The FDA granted Breakthrough Therapy designation in 2025 for neoadjuvant treatment of adults with primary uveal melanoma for whom enucleation had been recommended.

OptimUM-09 is the Phase 2 signal-generating study, with follow-up scheduled for ESMO. OptimUM-10 was designed as a randomized neoadjuvant Phase 3 study of about 450 patients; the May update targeted full enrollment by end-2027. The August 4 update subsequently highlighted recruitment considerations and a review of capital allocation, including whether OptimUM-09 evidence could support a clinical-guideline pathway instead of fully investing in the neoadjuvant registrational program. This is a reassessment, not an announced cancellation; the earlier enrollment target may no longer stand as a current commitment. August 4 business update

OptimUM-11: adjuvant therapy

IDEAYA and Servier announced first-patient dosing in OptimUM-11 on September 9. The global Phase 3 trial tests darovasertib plus crizotinib after local treatment in primary uveal melanoma patients at increased risk of metastasis. The study has therefore moved beyond the planned-start stage; the announcement contains no efficacy results. Approximately 450 patients are planned, regardless of HLA status, randomized 1:1 to 12 months of combination treatment or observation. The primary endpoint is relapse-free survival. IDEAYA retains U.S. regulatory and commercial rights, Servier holds rights outside the U.S., and the partners share trial development costs. This adjuvant trial is distinct from the metastatic-disease NDA, whose completion remains company-guided for H2 2026. Darovasertib remains investigational.

Company release

04 Pipeline ranking: the evidence behind the programs

A common biotech mistake is to assign equal weight to every colored bar on a pipeline slide. The correct approach is probability-weighted. Darovasertib has randomized registrational data. IDE849 has early human responses and a partner dataset. IDE397 has human monotherapy activity but a changed strategy. IDE892 has now entered Part 2 monotherapy expansion at projected target exposure, but no human efficacy dataset has been disclosed. IDE034 and IDE574 remain early. IDE161 is a mechanistically interesting combination tool whose standalone value remains uncertain.

IDE849: the most credible second pillar

IDE849, also known as SHR-4849, is a DLL3-targeted antibody-drug conjugate carrying a topoisomerase-I payload. IDEAYA licensed rights outside Greater China from Hengrui. DLL3 is highly expressed in small-cell lung cancer and several neuroendocrine malignancies, creating a biomarker-driven target. The program is strategically important because it gives IDEAYA exposure to a larger commercial market than uveal melanoma and connects directly to its DNA-damage-response expertise.

In March, IDEAYA reported that a 2.4 mg/kg every-three-week expansion cohort had produced multiple partial responses, including three responses among four SCLC patients previously treated with Imdelltra. The global study was also evaluating 3.5 mg/kg in escalation. Small denominators and early follow-up demand caution. The ESMO presentation from Hengrui will provide longer-term Chinese Phase 1 data, while IDEAYA targets a global monotherapy and combination update in H2 and a first registrational trial by year-end in its regions, including the United States. Hengrui is separately targeting registrational development in China.

The key IDE849 questions are not simply whether responses occur. Investors need response durability, dose intensity, hematologic and interstitial-lung-disease safety, activity after a DLL3 T-cell engager, consistency between Chinese and global populations, and a registrational design that can compete in a fast-moving SCLC landscape.

IDE397 and IDE892: a strategically coherent reset

Loss of MTAP creates a metabolic dependency on MAT2A and PRMT5. IDE397 inhibits MAT2A; IDE892 is designed to inhibit the MTA-bound form of PRMT5 with high selectivity. The combination thesis is biologically coherent: dual pressure on the same cancer-specific vulnerability may produce deeper activity at tolerable exposures. IDEAYA initiated the IDE892 plus IDE397 trial in June, focusing on MTAP-deleted pancreatic and non-small-cell lung cancers.

On July 27, IDEAYA said IDE892 had cleared multiple monotherapy dose cohorts and initiated Part 2 expansion after achieving projected efficacious human exposure with 24-hour target EC90 coverage. The MTD had still not been reached, and dose escalation was continuing in parallel. The company describes IDE892 as approximately 1,400-fold selective for MTA-PRMT5 cooperative binding over SAM-PRMT5 cooperative binding, with no intended brain penetration, a CYP3A4 IC50 above 45 micromolar and no time-dependent inhibition across seven major cytochrome P450 enzymes in the reported assays. Those properties may support combination development, but they remain company-reported pharmacology rather than proof of clinical benefit.

The IDE892 plus IDE397 combination escalation is ongoing in MTAP-deleted NSCLC and PDAC. IDEAYA also targets first-patient-in during H2 2026 for IDE892 plus Roche’s RG6505 pan-RAS inhibitor in MTAP-deleted PDAC and has scheduled a London Investor R&D Day on its MTAP/CDKN2A and KRAS strategy in pancreatic cancer for November 16, 2026. Preclinical models showed complete and durable combination responses, but the market should not pay full value for preclinical synergy. The next proof points are human safety at expansion doses, pharmacodynamic target suppression, early antitumor activity and evidence that combinations can outperform monotherapy without collapsing the therapeutic window.

IDEAYA’s decision to conclude enrollment in the IDE397/Trodelvy combination programs was a strategic reset. It allows capital to be concentrated on wholly owned combinations and avoids dependence on an external ADC. It also means older expectations for a Gilead-supported path should be removed from valuation models.

IDE034, IDE161 and IDE574

IDE034 is designed to bind both B7H3 and PTK7 and internalize efficiently when the two targets are co-expressed on the same tumor cell. The intended advantage is greater tumor selectivity and a wider therapeutic window than a monovalent ADC. That differentiation must be proven with human safety and efficacy; bispecific targeting can improve selectivity, but it can also complicate expression thresholds and patient selection.

IDE161 inhibits PARG, an enzyme involved in removing poly-ADP-ribose. By allowing DNA lesions to accumulate, PARG inhibition could enhance the activity of TOP1-payload ADCs. The IDE849/IDE161 combination is therefore more important than the stand-alone PARG narrative. A successful combination would validate IDEAYA’s platform logic and could potentially extend across proprietary or external ADCs.

IDE574 is an oral dual KAT6/7 inhibitor. IDEAYA argues that simultaneous inhibition may produce greater and more durable antitumor effects than KAT6-selective approaches while sparing KAT5 and KAT8, which are important for normal cellular function. The Phase 1 study includes breast, prostate, colorectal and lung cancers. At this point, investors should assign option value, not a product-level valuation. Early safety, pharmacodynamic target engagement and signs of activity in biologically selected patients will determine whether it graduates into the investable pipeline.

The IDE849 Phase 3 design, and what the Genentech collaboration adds

On August 31, 2026 IDEAYA said an FDA Type C meeting had settled the design of a registrational Phase 3 for IDE849, its DLL3-targeting Topo-I-payload antibody drug conjugate, in extensive stage small cell lung cancer. The company is targeting initiation by year-end 2026. The planned study enrols approximately 400 ES-SCLC patients previously treated with tarlatamab, randomised 1:1 between IDE849 monotherapy and an investigator’s choice arm of topotecan and amrubicin. The primary endpoint for accelerated approval is overall response rate by blinded independent central review; the primary endpoint for full approval is median overall survival. Secondary endpoints include median duration of response by BICR, progression free survival and safety.

Three things in that paragraph are not yet settled, and the company flags them itself. The dose is still open: the ongoing global Phase 1 (NCT07174583) is evaluating expansion doses of 2.4 mg/kg and 3.5 mg/kg intravenously every three weeks to pick the recommended Phase 3 dose. The FDA’s feedback from a Type C meeting is preliminary and nonbinding, and the agency may still require changes to the design, endpoints, population or statistical plan, or additional data. And the trial has not opened. What is dated is the evidence flow: clinical updates in 100 ES-SCLC and NEC patients from partner Hengrui at ESMO 2026 and from the IDEAYA-sponsored Phase 1/2 in Q4 2026.

IDE849 is also running in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi and with IDEAYA’s PARG inhibitor IDE161, to shape a possible first-line SCLC registrational design. IDEAYA estimates the annual United States incidence of SCLC and NEC at approximately 34,000 and 19,000 patients.

Separately, on August 19, 2026, IDEAYA entered a clinical collaboration with Genentech, of the Roche Group, pairing its Phase 1 MTA-cooperative PRMT5 inhibitor IDE892 with Genentech’s KRAS G12D inhibitor GDC-7035 (RG6620) in pancreatic ductal adenocarcinoma carrying both an MTAP deletion and a KRAS G12D mutation, a combination of alterations estimated to co-occur in up to approximately 15% of PDAC patients, who have no approved targeted option. The economics matter as much as the biology: Genentech sponsors the trial and IDEAYA supplies IDE892, with joint governance, and each company retains all commercial rights to its own compound. No upfront, milestone or royalty terms are described, so none are reported here. This is the second Roche-group pairing for IDE892, after the RG6505 combination cohort in MTAP-deleted RAS-mutant PDAC planned for the second half of 2026.

Sources: IDEAYA press release, August 31, 2026 and IDEAYA press release, August 19, 2026. The August 31 release spells the control agent “ambrucin” in the body and “amrubicin” in its own FAQ; amrubicin, the existing agent, is the correct name.

05 Cash fortress — with a dilution footnote big enough to matter

At June 30, 2026, IDEAYA held approximately $1.24 billion in cash, cash equivalents and marketable securities, up from $972.9 million at March 31 after the June offering and the at-the-market programme. Q2 collaboration revenue was $8.9 million, research and development expense was $108.7 million, general and administrative expense was $22.5 million and net loss was $112.5 million, or $1.22 per share. For the first half, revenue was $15.4 million, the net loss was $211.0 million and net cash used in operations was $163.4 million. Net cash used in operations is the cleaner runway input than net loss because stock compensation and working-capital movements affect the accounting result.

Management had guided that the balance sheet could fund operations into 2030 before the June equity raise. The June transaction therefore looks like opportunistic financing after clinical de-risking rather than emergency financing. That is positive for program continuity. It is not free capital.

What the June raise actually added

IDEAYA sold 7,222,225 common shares at $27.00, including the underwriters’ option exercised in full, and issued pre-funded warrants covering 5,555,576 shares at $26.9999 with a $0.0001 exercise price. Gross proceeds were approximately $345 million. The Q2 10-Q reports net proceeds of $323.4 million after underwriting discounts, commissions and offering expenses, marginally below the approximately $323.6 million estimated in the June 10 Form 8-K.

The company also sold 1,196,423 shares through the ATM during the second quarter at a weighted-average price of approximately $28.38, for net proceeds of $33.1 million. Approximately $122.6 million of capacity remained under that agreement at June 30, 2026. These ATM shares are separate from the June underwritten offering.

At June 30, 2026, the Q2 Form 10-Q reports 96,375,637 common shares and 6,430,711 pre-funded warrant shares: 102,806,348 economic equivalents, calculated before options. Reported cash, equivalents and securities were $1,242.889 million. The 1,196,423 ATM shares were issued during Q2, not after the quarter. These reported figures replace the earlier March-based cash bridge.

Runway quality

IDEAYA’s cash is unusually strong for a pre-commercial biotech, but the cost structure is also moving higher. Darovasertib commercial preparation, manufacturing inventory, multiple global trials, several Phase 1 programs and larger registrational studies can raise both R&D and G&A. The Q1 year-over-year increase in R&D from $70.9 million to $95.7 million and in G&A from $13.5 million to $19.4 million shows that scaling is already underway.

The main benefit of the financing is strategic independence. IDEAYA can negotiate partnerships from strength, fund launch readiness and wait for better data before monetizing assets. The main drawback is that per-share success must clear a higher denominator. The company can create enterprise value and still produce less upside per share than a model using the old count.

06 Commercial opportunity and competition

IDEAYA estimates more than 10,000 annual primary uveal melanoma cases across North America, Europe and Australia, including more than 3,000 in the United States, and says roughly half of primary patients eventually develop metastatic disease. These are company estimates, not a guaranteed addressable market. The actual treated population will be narrowed by HLA status, line of therapy, performance status, liver burden, access, competing treatments and physician practice.

For the initial HLA-negative metastatic indication, darovasertib’s strongest commercial attributes are a randomized dataset, oral administration and a broad response signal. The hurdles are small-patient-population identification, specialist concentration, combination management, reimbursement and the need to establish the regimen within multidisciplinary liver-focused care.

Existing therapies define different competitive segments

• Kimmtrak (tebentafusp): FDA-approved for HLA-A*02:01-positive unresectable or metastatic uveal melanoma. It established a systemic standard in the HLA-positive population but does not serve HLA-negative patients. Its label requires weekly intravenous dosing, and the first three infusions require extended monitoring because of cytokine-release-syndrome risk.
• Hepzato Kit: an FDA-approved liver-directed melphalan delivery system for defined adults with unresectable hepatic metastases from uveal melanoma. It addresses liver-dominant disease through a complex procedure and REMS-based care infrastructure. It is not a simple direct substitute for an oral systemic regimen, but it competes for eligible patients and treatment sequencing.
• Checkpoint inhibitors and chemotherapy: used historically despite limited activity in many patients. They formed the investigator-choice context in the registrational study. Practice can still include systemic immunotherapy, clinical trials and local liver procedures.

The broader commercial question is whether darovasertib becomes the backbone across HLA groups and disease stages. A metastatic HLA-negative approval would validate the mechanism and build prescribing familiarity. HLA-positive data could expand use, but Kimmtrak creates a higher comparative bar. Neoadjuvant and adjuvant success could add larger-duration markets, yet those settings require longer trials and stronger long-term safety confidence.

Pipeline competition is more intense than the lead indication

DLL3 is a crowded target, with an approved T-cell engager and multiple ADCs and biologics in development. MTAP deletion is also one of oncology’s most competitive emerging precision markets, with several companies developing MTA-cooperative PRMT5 inhibitors, MAT2A inhibitors or combinations. This competition is healthy validation of the biology, but it compresses the time available to show differentiation.

Commercial execution checklist

Patient finding

HLA testing, referral pathways and coordination with ocular oncology centers must be systematic.

Launch readiness

Sales-force focus, medical affairs, supply, payer dossiers and physician education must be ready before approval.

Combination supply

Crizotinib availability, labeling and reimbursement must work operationally with darovasertib.

Real-world tolerability

Syncope, hypotension, diarrhea and dose modification require practical protocols beyond the trial environment.

Guidelines

NCCN and international guideline inclusion can accelerate adoption, especially in a rare specialist market.

Ex-U.S.

Servier must execute filings, reimbursement and launch outside the United States; royalties depend on its performance.

07 Management, governance and ownership

Founder Yujiro S. Hata became board chairman in June 2026 while remaining chief executive. He launched IDEAYA as its first employee in 2015 and previously worked in strategy and corporate development at Flexus, Onyx and Enanta. The current leadership team includes chief medical officer Darrin Beaupre, Michael White (President, Research and Development since September 28, 2026; previously chief scientific officer since 2021), chief development officer Theodora Ross, chief financial officer Joshua Bleharski, chief commercial officer Stu Dorman, chief legal officer Douglas Snyder and chief business officer Daniel Simon.

An insider filing followed on October 6, 2026. Hata, listed as chief executive on the notice, filed a Form 144 for the proposed sale through J.P. Morgan Securities of 230,316 common shares acquired that day through a stock option exercise paid in cash, with an aggregate market value of $8,804,981, about $38.23 a share. The notice cites a Rule 10b5-1 trading plan adopted on July 7, 2026, says the sales will include cashless option exercises over the following three months, and reports no sales in the prior three months. The amount equals about 0.24% of the 96,489,484 shares the notice lists as outstanding, a calculation. A Form 144 announces an intended sale; executed quantities and prices would appear in a Form 4. Form 144 (SEC)

That bench is appropriate for the transition from development to commercialization. The potential concern is board concentration: combining CEO and chair roles can reduce structural independence, even though the remaining directors are described as independent. The board’s ability to challenge launch spending, pipeline prioritization and compensation becomes more important as the organization scales.

The 2026 proxy reported beneficial ownership using 87.86 million March 31 shares. FMR was listed at 14.4%, BlackRock at 8.1%, Janus Henderson at 7.3% and Capital Research Global Investors at 6.0%, based on filings with different measurement dates. Hata beneficially owned 2.7% including options exercisable within 60 days, while all directors and executive officers as a group held 4.7% on the proxy methodology. These percentages were calculated before the June financing and no longer reflect current ownership.

Capital allocation scorecard

• Positive: securing $210 million upfront from Servier while retaining U.S. darovasertib economics.
• Positive: raising capital after a major clinical de-risking event, extending strategic flexibility.
• Positive: pruning IDE275, IDE705 and the Trodelvy combination rather than defending sunk costs.
• To monitor: the high number of concurrent programs and the risk that a cash-rich company over-expands.
• To monitor: equity compensation. At March 31, 14.8 million options were outstanding, a meaningful potential source of dilution and employee alignment.

08 Risks: what can break the thesis

The principal failure tests are an FDA requirement for evidence that the current package cannot supply, a mature survival trend against the combination, an unexpected serious safety signal, or repeated manufacturing and launch delays. Pipeline diversification would offer limited protection if early IDE849 or MTAP results fail to mature while spending accelerates. Partner execution and further equity issuance remain additional risks. The clinical, commercial and financing sections above describe these mechanisms; none is eliminated by the June cash balance.